| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/16/2006 | US20060034916 Compositions and methods for nutrition supplementation |
| 02/16/2006 | US20060034915 Dexamethasone-containing formulations for oral administration as well the process for manufacturing required therefor |
| 02/16/2006 | US20060034914 Direct compression polymer tablet core |
| 02/16/2006 | US20060034912 Compositions and methods for nutrition supplementation |
| 02/16/2006 | US20060034911 New oral immediated release dosage form |
| 02/16/2006 | US20060034908 Manufacturing process for liposomal preparations |
| 02/16/2006 | US20060034906 Treatment of lung diseases and pre-lung disease conditions |
| 02/16/2006 | US20060034900 Adhesive preparation containing fentanyl |
| 02/16/2006 | US20060034896 triglycerides such as triester of caprylic acid or capric acid with glycerin, used along with foods or drugs, without concerning about side effects and restrictive diets |
| 02/16/2006 | US20060034895 Supplement food for low blood glucose recovery |
| 02/16/2006 | US20060034893 Use of hesperidin or one of its derivatives for making a medicine for bone formation stimulation |
| 02/16/2006 | US20060034892 Composition for topical administration |
| 02/16/2006 | US20060034878 Iodized oil |
| 02/16/2006 | US20060034872 Compositions and methods for preventing abuse of orally administered medications |
| 02/16/2006 | US20060034851 Targeted therapeutic delivery of vitamin D compounds |
| 02/16/2006 | US20060034847 Methods of treating a subject for a condition |
| 02/16/2006 | US20060034837 Method and agents for the prevention, inhibition and therapy of cancers |
| 02/16/2006 | US20060034832 Cell death inhibitor |
| 02/16/2006 | US20060034831 Combination therapy for diabetes, obesity and cardiovascular diseases using GDF-8 inhibitors |
| 02/16/2006 | US20060034824 Pharmaceutical composition comprising carriers for products |
| 02/16/2006 | US20060034823 Method of production and use of crotoxin as an analgesic |
| 02/16/2006 | US20060034822 Hyaluronidase preparation for ophthalmic administration and enzymatic methods for accelerating clearance of hemorrhagic blood from the vitreous body of the eye |
| 02/16/2006 | US20060034817 Cloning, overexpression and therapeutic use of bioactive histidine ammonia lyase |
| 02/16/2006 | US20060034801 Method for treating or preventing ischemia reperfusion injury or multi-organ failure |
| 02/16/2006 | US20060034799 Tissue protective cytokines for the protection, restoration, and enhancement fo responsive cells, tissues and organs |
| 02/16/2006 | US20060034798 Water-in-oil emulsions with ethylene oxide groups, compositions, and methods |
| 02/16/2006 | US20060034797 Polymeric micromulsions |
| 02/16/2006 | US20060034796 Pharmaceutical compositions of beta-lapachone and beta-lapachone analogs with improved tumor targeting potential |
| 02/16/2006 | US20060034795 Cytostatic drug composition |
| 02/16/2006 | US20060034786 and/or for preventing and/or for limiting depigmentation and/or whitening of the skin and/or skin appendages, notably for preventing and/or limiting canities; stimulates melanin synthesis by melanocytes by specifically inhibiting the degradation of prostaglandins synthesized by these melanocytes |
| 02/16/2006 | US20060034781 Peroral preparation for prevention or treatment of atopic dermatatis |
| 02/16/2006 | US20060034779 Foamable compositions containing vitamin D3 analogues, processes for preparing same and methods of treatment utilizng same |
| 02/16/2006 | US20060034776 Inhalable medicaments containing a new anticholinergic, corticosteroids, and betamimetics |
| 02/16/2006 | US20060034775 Aerosol formulation for inhalation containing an anticholinergic |
| 02/16/2006 | US20060034763 Therapeutic use of resveratrol for hyperglycemia |
| 02/16/2006 | US20060032768 Prefilled injector package and sterilizing or disinfecting method therefor |
| 02/16/2006 | US20060032400 Modified hydroxyethyl- or hydroxypropyl-substituted starch product for clinical use, which has a degree of branching of 8-10 mol %, a degree of substitution of up to 0.3, an average molecular weight of 10000- 450000; product is not derived from an amylopectin fraction |
| 02/16/2006 | DE29924843U1 Pellet for treating fungal infection comprises core coated with film of water soluble polymer and antifungal agent |
| 02/16/2006 | DE20321153U1 Transdermal therapeutic system containing the analgesic fentanyl, comprising penetration accelerator-free drug-containing adhesive matrix of acrylate copolymer with hydroxyethyl acrylate and vinyl acetate units |
| 02/16/2006 | DE102004036092A1 Haut- und/oder Haarmittel enthaltend Verbindungen zur Steigerung der Hautbräunung Skin and / or hair compositions comprising compounds for increasing skin tanning |
| 02/16/2006 | DE102004035322A1 Selektive Hemmstoffe humaner Corticoidsynthasen Selective inhibitors of human Corticoidsynthasen |
| 02/16/2006 | DE102004035227A1 mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen mRNA mixture for vaccination against tumors |
| 02/16/2006 | DE102004035203A1 Substituierte Chinolone Substituted Quinolones |
| 02/16/2006 | DE102004035113A1 Composition for treating symptoms of cystic fibrosis comprises alpha-lipoic acid or a derivative thereof as the sole active ingredient |
| 02/16/2006 | DE102004034913A1 Neue Verbindungen, die Faktor Xa-Aktivität inhibieren Novel compounds which inhibit factor Xa activity |
| 02/16/2006 | DE102004034682A1 Verkürztes Verfahren zur Herstellung von chiralem Lobelin Shortened process for the preparation of chiral lobeline |
| 02/16/2006 | DE102004034640A1 Verfahren zur systemischen Biokorrektur eines Organismus Method for systemic Biokorrektur an organism |
| 02/16/2006 | DE102004034573A1 Composition for treating pulmonary and coronary vascular diseases and metabolic diseases comprises L-arginine/ornithine, L-lysine, L-carnitine and L-cysteine in an isotonic sodium chloride solution |
| 02/16/2006 | DE102004034380A1 Use of a composition comprising a TRAIL protein and an indole or benzimidazole derivative to prepare a medicament for treating pain |
| 02/16/2006 | DE102004033902A1 New tetrahydrocarbazole compounds are neurokinin-1 receptor antagonists useful to treat or prevent e.g. pubertas praecox, hirsutism, polycystic ovary syndrome, hormone dependent neoplastic diseases and Alzheimer's disease |
| 02/16/2006 | DE102004033405A1 New 7-phenylamino-quinolone or 1,8-naphthyridone derivatives, useful e.g. for treating type II diabetes or arteriosclerosis, are inhibitors of glycogen phosphorylase |
| 02/16/2006 | DE102004032878A1 Verwendung von Alkyloxyalkansäureamiden insbesondere als Aromastoffe sowie neue Alkyloxyalkansäureamide Use of Alkyloxyalkansäureamiden especially as flavorings and new Alkyloxyalkansäureamide |
| 02/16/2006 | DE102004032823A1 New D-xylopyranosyl-substituted phenyl compounds are sodium-dependent glucose cotransporter inhibitors useful to prevent or treat e.g. diabetes mellitus, complications of diabetes, metabolic acidosis or ketosis |
| 02/16/2006 | DE102004032651A1 Verwendung von substituierten 2-Thio-3,5-dicyano-4-phenyl-6-aminopyriden bei der Behandlung von Übelkeit und Erbrechen Use of substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyriden in the treatment of nausea and vomiting |
| 02/16/2006 | DE102004032440A1 Use of 6,7,8-trihydroxy-2H-1-benzopyran-2-ones to treat or prevent diseases involving oxidative stress and/or inflammatory reactions |
| 02/16/2006 | DE102004024504A1 Neue Cylopenta[b]benzofuran-Derivate und ihre Verwendung New Cylopenta [b] benzofuran derivatives and their use |
| 02/16/2006 | CA2736965A1 Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof |
| 02/16/2006 | CA2615563A1 Compositions and methods for controlling infections |
| 02/16/2006 | CA2584970A1 Method for the treatment of mammalian skin tissues via pulse irradiation in the presence of a photoactive compound |
| 02/16/2006 | CA2578478A1 Product and process for inhibition of biofilm development |
| 02/16/2006 | CA2576949A1 Pyrazolo[1,5-a]pyrimidine derivatives |
| 02/16/2006 | CA2576667A1 Hydroxyamide compounds having activity as inhibitors of histone deacetylase (hdac) |
| 02/16/2006 | CA2576581A1 Substituted indole compounds, their preparation and use in medicaments |
| 02/16/2006 | CA2576576A1 Gastrin-specific interfering rna |
| 02/16/2006 | CA2576544A1 Pyrazolone compounds useful for treatment of cerebrovascular disorders associated with ischemic stroke |
| 02/16/2006 | CA2576505A1 Combination of bupropion and a second compound for affecting weight loss |
| 02/16/2006 | CA2576407A1 Substituted phenylacetamides and their use as glucokinase activators |
| 02/16/2006 | CA2576386A1 Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof |
| 02/16/2006 | CA2576385A1 Novel formulation for l-tryptophane comprising carbidopa/benserazide |
| 02/16/2006 | CA2576258A1 Novel quinoxalinone norepinephrine reuptake inhibitors for the treatment of central nervous system disorders |
| 02/16/2006 | CA2576257A1 Anti-inflammatory agents |
| 02/16/2006 | CA2576254A1 Compounds which potentiate glutamate receptor and uses thereof in medicine |
| 02/16/2006 | CA2576196A1 Novel statin pharmaceutical compositions and related methods of treatment |
| 02/16/2006 | CA2576190A1 Iron chelators for treating radiocontrast-associated renal dysfunction |
| 02/16/2006 | CA2576153A1 Use of n-desmethylclozapine to treat human neuropsychiatric disease |
| 02/16/2006 | CA2576096A1 Substituted, bicyclic 8-pyrrolidinoxanthines, method for the production thereof and their use as medicaments |
| 02/16/2006 | CA2576090A1 Substituted bicyclic 8-pyrrolidino-xanthines and use thereof as inhibitors of the dipeptidyl peptidase iv |
| 02/16/2006 | CA2576041A1 Oxazolidinones containing oxindoles as antibacterial agents |
| 02/16/2006 | CA2575995A1 Treatment for methamphetamine addiction and reduction of methamphetamine use using serotonin antagonists |
| 02/16/2006 | CA2575980A1 Combination of a selective noradrenaline reuptake inhibitor and a pdev inhibitor |
| 02/16/2006 | CA2575947A1 Modulation of bio-electrical rhythms via a novel engineering approach |
| 02/16/2006 | CA2575932A1 Pharmaceutical formulations comprising pleconaril for the treatment of airway diseases |
| 02/16/2006 | CA2575916A1 Methods and compositions to reduce tissue irritation in parenteral formulations |
| 02/16/2006 | CA2575907A1 Novel uses of 2-phenyl-substituted imidazotriazinone derivatives |
| 02/16/2006 | CA2575904A1 Substituted 8-aminoalkylthio-xanthines, and the use thereof as inhibitors of the dipeptidyl peptidase iv |
| 02/16/2006 | CA2575849A1 Combination therapies employing vitamin b6 related compounds and ace inhibitors and uses thereof for the treatment of diabetic disorders |
| 02/16/2006 | CA2575808A1 Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds |
| 02/16/2006 | CA2575736A1 Sulfonyl compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 |
| 02/16/2006 | CA2575702A1 Oxindole oxazolidinones as antibacterial agents |
| 02/16/2006 | CA2575618A1 Crystalline polymorph of pipindoxifene hydrochloride monohydrate |
| 02/16/2006 | CA2575617A1 Lysis/resealing process and device for incorporating an active ingredient in erythrocytes |
| 02/16/2006 | CA2575588A1 Medicaments for the prevention or treatment of alveolar pneumonia comprising an anticholinergic |
| 02/16/2006 | CA2575582A1 17-desmethylrapamycin and analogues thereof, methods for their production and their use as immunosupressants, anticancer agents, antifungal agents, etc. |
| 02/16/2006 | CA2575571A1 2,8-disubstituted naphthyridine derivatives |
| 02/16/2006 | CA2575541A1 New pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders |
| 02/16/2006 | CA2575486A1 Crystalline polymorph of pipindoxifene hydrochloride monohydrate |
| 02/16/2006 | CA2575447A1 A method of improving anticancer effect of pulsatillae radix and a composition prepared by the method |
| 02/16/2006 | CA2575430A1 1,3-disubstituted heteroaryl nmda/nr2b antagonists |
| 02/16/2006 | CA2575316A1 Trifluoromethyl substituted benzamides as kinase inhibitors |
| 02/16/2006 | CA2575300A1 Treatment of neurodegenerative diseases by the use of degs inhibitors |